Bookmark of this page has been deleted.
Recro Strengthens Leadership Team With Key Executive and Board Appointments
Company Names CDMO Industry Thought Leader, Jim Miller, to Board of Directors and Selects Ryan D. Lake as Dedicated Chief Financial Officer
Recent Appointments, including CEO David Enloe, Provide Experienced Leadership to Drive Growth for Company’s Unique End-to-End CDMO Business in Rapidly Expanding Manufacturing Services Market
MALVERN, Pa., Feb. 11, 2021 (GLOBE NEWSWIRE) Recro Pharma, Inc. (“Recro”; NASD: REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the continued strengthening of its leadership through key appointments to its management team and board of directors. Recro named James (“Jim”) Miller, a highly regarded CDMO industry thought leader, to its board of directors. Additionally, the c
Recro Announces Executive Changes David Enloe Named President and Chief Executive Officer
December 16, 2020 07:00 ET | Source: Recro Pharma, Inc. Recro Pharma, Inc. Malvern, Pennsylvania, UNITED STATES
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today.
Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDMO businesses. Most recentl
Recro Grants Inducement Award to New Chief Executive Officer
MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that it granted an inducement award to its newly-appointed President and Chief Executive Officer, David Enloe.
The award consists of 217,822 restricted stock units and an option to purchase 194,175 shares of Recro’s common stock. The award was granted on December 15, 2020 pursuant to the NASDAQ inducement grant exception as a component of Mr. Enloe’s compensation and was granted as an inducement material to his acceptance of employment with Recro in accordance with NASDAQ Listing Rule 5635(c)(4). With regard to the restricted stock units, 19,802 will vest in full on December 15, 2021; 1
Recro Grants Inducement Award to New Chief Executive Officer – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Published: Dec 16, 2020
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today.
Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDMO businesses. Most recently, he served as President and Chief Executive Officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO. Under Mr. Enloe’s leadership, Aji Bio-Pharma’s revenues have increased over 50% in a four-year period and he led the